Virax Debt To Equity from 2010 to 2025

VRAX Stock  USD 1.67  0.04  2.34%   
Virax Biolabs Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2025. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.0376
Current Value
0.0395
Quarterly Volatility
0.35400827
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 88.1 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 10.3, Dividend Yield of 0.0 or PTB Ratio of 0.26. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Check out the analysis of Virax Biolabs Correlation against competitors.

Latest Virax Biolabs' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Virax Biolabs Group over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Virax Biolabs' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.00 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Virax Debt To Equity Regression Statistics

Arithmetic Mean(0.46)
Geometric Mean0.22
Coefficient Of Variation(76.95)
Mean Deviation0.32
Median(0.72)
Standard Deviation0.35
Sample Variance0.13
Range0.7608
R-Value0.86
Mean Square Error0.04
R-Squared0.73
Significance0.000023
Slope0.06
Total Sum of Squares1.88

Virax Debt To Equity History

2025 0.0395
2024 0.0376
2023 0.0418
2022 0.016
2021 -0.003856
2020 -0.3

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.04  0.04 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.